A5057981061- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Blood groups and transfusion
- Prenatal Screening and Diagnostics
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
- Beetle Biology and Toxicology Studies
- CNS Lymphoma Diagnosis and Treatment
- Nutrition and Health in Aging
- Fungal Infections and Studies
- Acute Myeloid Leukemia Research
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
Agostino Gemelli University Polyclinic
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
Università Cattolica del Sacro Cuore
2018-2023
Azienda Ospedaliera Sant'Andrea
2017-2020
Sapienza University of Rome
2015-2020
This study was aimed at evaluating the feasibility, safety, immunologic and clinical responses in patients with follicular lymphoma treated monocyte-derived dendritic cells generated presence of IFNα GM-CSF (IFN-DC) combination low doses rituximab.Firstly, we analyzed vitro vivo properties IFN-DC against lymphoma. Thus, performed a phase I trial 8 refractory relapsed based on sequential intranodal injections low-dose rituximab unloaded report clinical, results enrolled patients.Preclinical...
Background/Objectives: Treatments for multiple myeloma (MM) have expanded in the last decade, and overall survival (OS) of MM patients (pts) is continuous improvement. With availability new treatments use high-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation (ASCT), median OS newly diagnosed (NDMM) pts 6–8 years. To date, approximately 50% 28% are still alive at 5 years 10 Few data reported concerning characteristics long-term pts. Methods: aim this...
Lymphoma treatments can produce adverse effects leading to a reduced quality-of-life (QoL). Besides, in patients ≥65years, it promote an accelerated geriatric decay. We conducted prospective study on supervised Exercise-Training (ET), consecutive, aged 18–80years, during anti-lymphoma treatments.16/30 (53%), median-age = 65.5y, participated the ET sessions, this was Interventional Group (IG); 14/30 (47%), 63y, were Reference (RG). Both groups fitness and QoL assessments, at baseline (T0),...
<div>AbstractPurpose:<p>This study was aimed at evaluating the feasibility, safety, immunologic and clinical responses in patients with follicular lymphoma treated monocyte-derived dendritic cells generated presence of IFNα GM-CSF (IFN-DC) combination low doses rituximab.</p>Patients Methods:<p>Firstly, we analyzed <i>in vitro</i> vivo</i> properties IFN-DC against lymphoma. Thus, performed a phase I trial 8 refractory relapsed based on sequential...
Pregnancy in women with Sickle Cell Disease (SCD) is a high-risk situation, especially during the third trimester of gestation and post-partum period, due to chronic hypoxia vaso-occlusive phenomena occurring maternal-fetal microcirculation: as result, unfavorable outcomes, such intra-uterine growth restriction, prematurity or fetal loss are more frequent SCD pregnancies. Therefore, there consensus on need for strict multidisciplinary follow-up within specialized structures. Transfusion...
Invasive fungal infection (IFI) remains the major complication in patients with either acute leukemia, allogeneic stem cell transplantation setting, or both, especially regarding pulmonary localization. We report an experience of a 74-year-old Caucasian male Philadelphia-positive (BCR-ABL p190) Common B-acute lymphoblastic leukemia (ALL) who developed due to Geosmithia argillacea. Furthermore, we describe management this and results microbiological tests useful guide treatment. All cases...
<p>CT-PET scan showing clinical response of Pt#2.</p>
<p>CT-PET scan showing clinical response of Pt#3</p>
<div>AbstractPurpose:<p>This study was aimed at evaluating the feasibility, safety, immunologic and clinical responses in patients with follicular lymphoma treated monocyte-derived dendritic cells generated presence of IFNα GM-CSF (IFN-DC) combination low doses rituximab.</p>Patients Methods:<p>Firstly, we analyzed <i>in vitro</i> vivo</i> properties IFN-DC against lymphoma. Thus, performed a phase I trial 8 refractory relapsed based on sequential...
<p>CT-PET scan showing clinical response of Pt#3</p>
<p>CT-PET scan showing clinical response of Pt#2.</p>
High dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care therapy for newly diagnosed multiple myeloma (NDMM) patients (pts). The anti-CD38 IgG1-k monoclonal antibody daratumumab (dara) demonstrated to improve depth and duration response in transplant eligible MM pts when added induction regimen. Recent studies have indicated a potential reduction yields exposed dara prior mobilization. We retrospectively evaluated 51 with NDMM managed at 8...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: High dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care therapy for newly diagnosed multiple myeloma (NDMM) patients (pts). The anti-CD38 IgG1-k antibody daratumumab (dara) demonstrated to improve depth duration response in transplant eligible MM pts when added induction regimen. Recent studies have indicated a potential reduction yields exposed dara prior mobilization...
Background: There is an unmet need for active treatments in elderly, non-FIT patients, with aggressive lymphomas, allowing to preserve patient's Quality of life (QoL). Moving forward setting up a suitable schedule, we devised metronomic chemotherapy (MTN-CHT) protocol, termed DEVEC, consisting prednisolone (PDN), cyclophosphamide (CTX), etoposide (ETO), oral vinorelbine (VRN) ± rituximab(RTX). Since February 2011, this MTN-CHT was adopted six clinical centres affiliated the FIL. Candidate...
7563 Background: Metronomic chemotherapy (MC) is an emerging approach in solid tumours. Since MC has been poorly investigated aggressive lymphomas 2011, we formulated a new oral regimen termed DEVEC (Deltacortene, Etoposide, Navelbine, Cyclophosphamide). Methods: The foresees induction and deescalated maintenance phase both consisting 6 cycles. Rituximab administered CD20+ cases. Patients with B T cell lymphomas, unsuitable for standard-chemotherapies, were enrolled Italian institutions....